Medicare Will Pay For Biosimilars Referencing Same Drug Equally, CMS Proposes
This article was originally published in The Pink Sheet Daily
Executive Summary
Biopharma manufacturers oppose placing all biosimilars referencing a product into the same code for Medicare Part B reimbursement.